To determine whether our GEMM Kras signature is representative of human KRAS mutant CRC tumors, we compared it to a human KRAS signature derived in the multivariable model with KRAS and BRAF mutation as covariates in PETACC-3 patients. This evidence concerns the gene BRAF and colorectal carcinoma.